Tiziana Life Sciences Ltd. Common Shares (TLSA)
TLSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TLSA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2018 |
| SEC CIK | 0001723069 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Bermuda |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Group's ability to continue as a going concern." | 20-F 2026-05-01 |
| Cash and burn | $4.0M cash; operating cash flow -$3.2M a quarter. | Report 2025-12-31 |
| Shares outstanding | 120,507,401 (2025-12-31); 111,462,617 a year earlier; 102,272,614 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-01-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PKF Littlejohn LLP, London, United Kingdom | PCAOB Form AP 2026-05-08 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-04-30 |
| Insider trades, 12 months | Bought $1.0M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$18.4M | -$12.8M | $4.0M | No debt tags | Needs four quarters | 20-F 2026-05-01 |
| FY 2024 2024-12-31 | Not filed | -$11.9M | -$1.5M | $3.7M | No debt tags | Needs four quarters | 20-F/A 2025-05-08 |
| FY 2023 2023-12-31 | Not filed | -$17.7M | -$15.7M | $1.2M | No debt tags | Needs four quarters | 20-F/A 2025-05-08 |
| FY 2022 2022-12-31 | Not filed | -$15.4M | -$19.6M | $18.1M | No debt tags | Needs four quarters | 20-F/A 2025-05-08 |
| FY 2021 2021-12-31 | Not filed | -$23.4M | -$21.8M | $42.2M | No debt tags | Needs four quarters | 20-F 2024-05-10 |
| FY 2020 2020-12-31 | Not filed | -$26.1M | -$11.3M | $65.8M | $324K | Needs four quarters | 20-F/A 2023-06-13 |
| FY 2019 2019-12-31 | Not filed | -$9.3M | -$6.8M | $200K | $313K | Needs four quarters | 20-F 2022-05-23 |
| FY 2018 2018-12-31 | Not filed | -$7.9M | -$4.6M | $5.3M | $302K | Needs four quarters | 20-F 2021-05-17 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-01-22 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-05-01 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 496 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.4% |
| 1 month | -47.7% |
| 3 months | -45.2% |
| Year to date | -61.7% |
| 1 year | -65.5% |
| From 52-week high | -68.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KALA | KALA BIO Inc. | $3.83 | -8.02% | $74.1M |
| RANI | Rani Therapeutics Holdings Inc. | $0.5403 | +2.66% | $75.4M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| CPIX | Cumberland Pharmaceuticals Inc. | $5.21 | -11.39% | $78.1M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier